Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation

Perenlei Enkhbaatar, Kenji Okajima, Kazunori Murakami, Mitsuhiro Uchiba, Hiroaki Okabe, Kazutoshi Okabe, Yasuo Yamaguchi

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Tissue factor pathway inhibitor (TFPI) is an important physiologic inhibitor of the extrinsic pathway of the coagulation system. We investigated whether recombinant TFPI (rTFPI) could reduce pulmonary vascular injury by inhibiting leukocyte activation in rats given lipopolysaccharide (LPS). Pre- or posttreatment of animals with rTFPI significantly inhibited LPS-induced pulmonary vascular injury, as well as coagulation abnormalities. rTFPI significantly inhibited increases in lung tissue levels of tumor necrosis factor (TNF)-α, cytokine-induced neutrophil chemoattractant, and myeloperoxidase. Expression of TNF-α messenger RNA in the lung after LPS administration was significantly reduced by rTFPI administration. However, neither DX-9065a, a selective inhibitor of Factor Xa, nor recombinant Factor VIIa treated with dansyl-glutamylglycylarginyl-chloromethyl ketone, a selective inhibitor of Factor VIIa, had any effects on LPS-induced pulmonary vascular injury despite their potent anticoagulant effects. rTFPI significantly inhibited TNF-α production by LPS-stimulated monocytes in vitro. rTFPI also significantly inhibited several formyl-Met-Leu-Phe-induced neutrophil functions, as well as increases in the expression of CD11b and CD18 on the neutrophil cell surface in vitro. Additionally, rTFPI inhibited increases in levels of intracellular calcium, a second messenger of neutrophil activation, in formyl-Met-Leu-Phe-stimulated neutrophils in vitro. These results strongly suggested that rTFPI reduces pulmonary vascular injury by inhibiting leukocyte activation, as well as coagulation abnormalities in rats given LPS.

Original languageEnglish (US)
Pages (from-to)1752-1759
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume162
Issue number5
StatePublished - 2000
Externally publishedYes

Fingerprint

Vascular System Injuries
Lung Injury
Lipopolysaccharides
Leukocytes
Neutrophils
methionyl-leucyl-phenylalanine
Tumor Necrosis Factor-alpha
lipoprotein-associated coagulation inhibitor
Factor VIIa
Lung
Neutrophil Activation
Factor Xa
Chemotactic Factors
Second Messenger Systems
Ketones
Anticoagulants
Peroxidase
Monocytes
Cytokines
Calcium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. / Enkhbaatar, Perenlei; Okajima, Kenji; Murakami, Kazunori; Uchiba, Mitsuhiro; Okabe, Hiroaki; Okabe, Kazutoshi; Yamaguchi, Yasuo.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 162, No. 5, 2000, p. 1752-1759.

Research output: Contribution to journalArticle

Enkhbaatar, Perenlei ; Okajima, Kenji ; Murakami, Kazunori ; Uchiba, Mitsuhiro ; Okabe, Hiroaki ; Okabe, Kazutoshi ; Yamaguchi, Yasuo. / Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. In: American Journal of Respiratory and Critical Care Medicine. 2000 ; Vol. 162, No. 5. pp. 1752-1759.
@article{11228eaba39141ee89de977fa2308dd1,
title = "Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation",
abstract = "Tissue factor pathway inhibitor (TFPI) is an important physiologic inhibitor of the extrinsic pathway of the coagulation system. We investigated whether recombinant TFPI (rTFPI) could reduce pulmonary vascular injury by inhibiting leukocyte activation in rats given lipopolysaccharide (LPS). Pre- or posttreatment of animals with rTFPI significantly inhibited LPS-induced pulmonary vascular injury, as well as coagulation abnormalities. rTFPI significantly inhibited increases in lung tissue levels of tumor necrosis factor (TNF)-α, cytokine-induced neutrophil chemoattractant, and myeloperoxidase. Expression of TNF-α messenger RNA in the lung after LPS administration was significantly reduced by rTFPI administration. However, neither DX-9065a, a selective inhibitor of Factor Xa, nor recombinant Factor VIIa treated with dansyl-glutamylglycylarginyl-chloromethyl ketone, a selective inhibitor of Factor VIIa, had any effects on LPS-induced pulmonary vascular injury despite their potent anticoagulant effects. rTFPI significantly inhibited TNF-α production by LPS-stimulated monocytes in vitro. rTFPI also significantly inhibited several formyl-Met-Leu-Phe-induced neutrophil functions, as well as increases in the expression of CD11b and CD18 on the neutrophil cell surface in vitro. Additionally, rTFPI inhibited increases in levels of intracellular calcium, a second messenger of neutrophil activation, in formyl-Met-Leu-Phe-stimulated neutrophils in vitro. These results strongly suggested that rTFPI reduces pulmonary vascular injury by inhibiting leukocyte activation, as well as coagulation abnormalities in rats given LPS.",
author = "Perenlei Enkhbaatar and Kenji Okajima and Kazunori Murakami and Mitsuhiro Uchiba and Hiroaki Okabe and Kazutoshi Okabe and Yasuo Yamaguchi",
year = "2000",
language = "English (US)",
volume = "162",
pages = "1752--1759",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation

AU - Enkhbaatar, Perenlei

AU - Okajima, Kenji

AU - Murakami, Kazunori

AU - Uchiba, Mitsuhiro

AU - Okabe, Hiroaki

AU - Okabe, Kazutoshi

AU - Yamaguchi, Yasuo

PY - 2000

Y1 - 2000

N2 - Tissue factor pathway inhibitor (TFPI) is an important physiologic inhibitor of the extrinsic pathway of the coagulation system. We investigated whether recombinant TFPI (rTFPI) could reduce pulmonary vascular injury by inhibiting leukocyte activation in rats given lipopolysaccharide (LPS). Pre- or posttreatment of animals with rTFPI significantly inhibited LPS-induced pulmonary vascular injury, as well as coagulation abnormalities. rTFPI significantly inhibited increases in lung tissue levels of tumor necrosis factor (TNF)-α, cytokine-induced neutrophil chemoattractant, and myeloperoxidase. Expression of TNF-α messenger RNA in the lung after LPS administration was significantly reduced by rTFPI administration. However, neither DX-9065a, a selective inhibitor of Factor Xa, nor recombinant Factor VIIa treated with dansyl-glutamylglycylarginyl-chloromethyl ketone, a selective inhibitor of Factor VIIa, had any effects on LPS-induced pulmonary vascular injury despite their potent anticoagulant effects. rTFPI significantly inhibited TNF-α production by LPS-stimulated monocytes in vitro. rTFPI also significantly inhibited several formyl-Met-Leu-Phe-induced neutrophil functions, as well as increases in the expression of CD11b and CD18 on the neutrophil cell surface in vitro. Additionally, rTFPI inhibited increases in levels of intracellular calcium, a second messenger of neutrophil activation, in formyl-Met-Leu-Phe-stimulated neutrophils in vitro. These results strongly suggested that rTFPI reduces pulmonary vascular injury by inhibiting leukocyte activation, as well as coagulation abnormalities in rats given LPS.

AB - Tissue factor pathway inhibitor (TFPI) is an important physiologic inhibitor of the extrinsic pathway of the coagulation system. We investigated whether recombinant TFPI (rTFPI) could reduce pulmonary vascular injury by inhibiting leukocyte activation in rats given lipopolysaccharide (LPS). Pre- or posttreatment of animals with rTFPI significantly inhibited LPS-induced pulmonary vascular injury, as well as coagulation abnormalities. rTFPI significantly inhibited increases in lung tissue levels of tumor necrosis factor (TNF)-α, cytokine-induced neutrophil chemoattractant, and myeloperoxidase. Expression of TNF-α messenger RNA in the lung after LPS administration was significantly reduced by rTFPI administration. However, neither DX-9065a, a selective inhibitor of Factor Xa, nor recombinant Factor VIIa treated with dansyl-glutamylglycylarginyl-chloromethyl ketone, a selective inhibitor of Factor VIIa, had any effects on LPS-induced pulmonary vascular injury despite their potent anticoagulant effects. rTFPI significantly inhibited TNF-α production by LPS-stimulated monocytes in vitro. rTFPI also significantly inhibited several formyl-Met-Leu-Phe-induced neutrophil functions, as well as increases in the expression of CD11b and CD18 on the neutrophil cell surface in vitro. Additionally, rTFPI inhibited increases in levels of intracellular calcium, a second messenger of neutrophil activation, in formyl-Met-Leu-Phe-stimulated neutrophils in vitro. These results strongly suggested that rTFPI reduces pulmonary vascular injury by inhibiting leukocyte activation, as well as coagulation abnormalities in rats given LPS.

UR - http://www.scopus.com/inward/record.url?scp=0033679115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033679115&partnerID=8YFLogxK

M3 - Article

C2 - 11069808

AN - SCOPUS:0033679115

VL - 162

SP - 1752

EP - 1759

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -